IP Library › Granted Patent US 9,591,835
Granted Patent B2
US 9,591,835 · App. 13/793,812 · Granted Mar 14, 2017

Genetically modified major histocompatibility complex animals

Inventors: Lynn MacDonald (White Plains, NY); Andrew J. Murphy (Croton-on-Hudson, NY); Cagan Gurer (Valhalla, NY); John McWhirter (Tarrytown, NY); Vera Voronina (Thornwood, NY); Faith Harris (Mamaroneck, NY); Sean Stevens (San Francisco, CA); Yingzi Xue (Ardsley, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K2217/15A01K2227/105A01K2267/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,591,835
App. No.
13/793,812
Granted
Mar 14, 2017
Kind
B2
Abstract

The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

Claims (11)

1. A mouse whose genome comprises at an endogenous H-2D locus a nucleotide sequence encoding a chimeric human/mouse HLA-B/H-2D polypeptide,

wherein the nucleotide sequence is in operable linkage with an endogenous mouse regulatory element and operably linked to a MHC I polypeptide leader encoding sequence,

wherein the nucleotide sequence comprises from 5′ to 3′

(i) a first nucleic acid sequence that encodes the α1, α2 and α3 domains of the human HLA-B polypeptide, which first nucleic acid sequence replaces a sequence encoding the α1, α2 and α3 domains of the mouse H-2D polypeptide at the endogenous H-2D locus, and

(ii) a second nucleic acid sequence that encodes the transmembrane and cytoplasmic domains of the mouse H-2D polypeptide,

wherein the mouse expresses, on the surface of nucleated cells, from the endogenous H-2D locus the chimeric HLA-B/H-2D polypeptide that comprises the α1, α2 and α3 domains of the human HLA-B polypeptide and transmembrane and cytoplasmic domains of the mouse H-2K polypeptide.

2. The mouse of claim 1 , wherein the human HLA-B polypeptide is an HLA-B27 polypeptide.

3. The mouse of claim 1 , wherein the MHC I polypeptide leader encoding sequence is an endogenous mouse H-2D leader encoding sequence.

4. The mouse of claim 1 , wherein the endogenous H-2D locus is an H-2D1 locus.

5. The mouse of claim 2 , wherein the HLA-B27 polypeptide is a polypeptide encoded by HLA-B27 allele subtypes B*2701-2759.

6. The mouse of claim 1 , wherein the mouse is homozygous at the endogenous H-2D locus for the nucleotide sequence encoding the chimeric human/mouse HLA-B/H-2D polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2013
From: MACDONALD, LYNN; MURPHY, ANDREW J.; GURER, CAGAN; MCWHIRTER, JOHN; VORONINA, VERA; HARRIS, FAITH; STEVENS, SEAN; XUE, YINGZI
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 030704/0891 →
Continuity (5)
Continuation In Part 13661159 · Oct 26, 2012
Provisional Application 61700908 · Sep 14, 2012
Provisional Application 61552582 · Oct 28, 2011
Provisional Application 61552587 · Oct 28, 2011
Related Publication 20130185819A1 · Jul 18, 2013